×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| NECTAR LIFESCIENCES LTD. | 2810.21 | -632.31 | 2806.71 | -2.82 | 519.0 | 30.5 |
| ONE GLOBAL SERVICE PROVIDER LI | NA | NA | NA | NA | 506 | 19.2 |
| JENBURKT PHARMACEUTICALS LTD. | NA | NA | NA | NA | 490 | 15.1 |
Nectar Lifesciences Limited, with Security Code 532649, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 388.8 | 394.1 | 398.0 | 452.2 | 441.4 | 359.3 | 428.1 | 455.0 | 430.7 | 280.7 |
| Expenses | 369.0 | 358.6 | 371.1 | 410.0 | 392.9 | 319.5 | 384.8 | 410.3 | 585.0 | 342.6 |
| Operating Profit | 19.8 | 35.5 | 26.9 | 42.2 | 48.5 | 39.8 | 43.3 | 44.7 | -154.3 | -61.9 |
| OPM % | 5.09% | 9.02% | 6.75% | 9.33% | 10.99% | 11.08% | 10.12% | 9.83% | -35.83% | -22.05% |
| Other Income | 17.9 | 0.5 | 10.6 | 0.5 | 1.5 | 0.6 | 0.7 | 0.6 | 0.1 | 0.4 |
| Interest | 19.7 | 17.6 | 20.5 | 24.8 | 24.2 | 20.0 | 19.8 | 17.1 | 17.7 | 18.7 |
| Depreciation | 14.8 | 15.3 | 15.3 | 15.4 | 14.7 | 15.5 | 15.5 | 15.6 | 15.8 | 16.5 |
| Profit before tax | 3.2 | 3.1 | 1.6 | 2.5 | 11.1 | 4.9 | 8.7 | 12.5 | -187.7 | -96.8 |
| Tax % | 68.2% | -40.5% | -38.1% | -36.2% | -94.6% | 39.6% | -35.4% | 37.5% | 30.7% | 34.6% |
| Net Profit | 5.4 | 1.8 | 1.0 | 1.6 | 0.6 | 3.0 | 5.6 | 7.8 | -130.1 | -63.2 |
| EPS in Rs | 0.24 | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.8 | -2.82 |
| Metrics | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 388.6 | 344.1 | 388.8 | 394.1 | 398.0 | 452.2 | 441.4 | 359.3 | 428.1 | 455.0 |
| Expenses | 396.0 | 342.7 | 370.7 | 358.6 | 371.1 | 410.0 | 392.9 | 319.5 | 384.8 | 410.3 |
| Operating Profit | -7.4 | 1.4 | 18.1 | 35.5 | 26.9 | 42.2 | 48.5 | 39.8 | 43.3 | 44.7 |
| OPM % | -1.9% | 0.42% | 4.65% | 9.02% | 6.75% | 9.33% | 10.99% | 11.08% | 10.12% | 9.83% |
| Other Income | 10.7 | 13.2 | 17.9 | 0.5 | 10.6 | 0.5 | 1.5 | 0.6 | 0.7 | 0.6 |
| Interest | 21.0 | 17.5 | 19.7 | 17.6 | 20.5 | 24.8 | 24.2 | 20.0 | 19.8 | 17.1 |
| Depreciation | 14.8 | 14.8 | 14.8 | 15.3 | 15.3 | 15.4 | 14.7 | 15.5 | 15.5 | 15.6 |
| Profit before tax | -32.5 | -17.6 | 1.5 | 3.1 | 1.6 | 2.5 | 11.1 | 4.9 | 8.7 | 12.5 |
| Tax % | -30.8% | -47.1% | 144.6% | -40.5% | -38.1% | -36.2% | -94.7% | -39.6% | -35.4% | -37.5% |
| Net Profit | -22.5 | -9.3 | 3.7 | 1.8 | 1.0 | 1.6 | 0.6 | 3.0 | 5.6 | 7.8 |
| EPS in Rs | -1 | -0.41 | 0.16 | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -10% |
| 3 Years: | 3% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -23% |
| 5 Years: | -37% |
| 3 Years: | 28% |
| TTM: | 74% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 13% |
| 3 Years: | -2% |
| 1 Year: | -29% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -10% |
| 3 Years: | 3% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -22% |
| 5 Years: | -37% |
| 3 Years: | 28% |
| TTM: | 110% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 13% |
| 3 Years: | -2% |
| 1 Year: | -29% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|